Literature DB >> 11393699

High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy.

P Langmann1, D Schirmer, T Väth, M Zilly, H Klinker.   

Abstract

A new high-performance liquid chromatographic method for the determination of efavirenz in human plasma is described. Quantitative recovery following liquid-liquid extraction with diethylether from 200 microl of human plasma was achieved. Subsequently, the assay was performed with 67 mM potassium dihydrogen phosphate-acetonitrile as a mobile phase, a XTerraRP 18 column protected with a Phenomenex C18 column and UV detection at 246 nm. Linear standard curves were obtained for concentrations ranging from 25 to 15,000 ng/ml. The calculated intra- and inter-day coefficients of variation were below 10%.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393699     DOI: 10.1016/s0378-4347(01)00059-7

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  7 in total

Review 1.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  In vitro activity of antiretroviral drugs against Plasmodium falciparum.

Authors:  Christian Nsanzabana; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.

Authors:  Ralf Winzer; Peter Langmann; Michael Zilly; Franz Tollmann; Jörg Schubert; Hartwig Klinker; Benedikt Weissbrich
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-01-20       Impact factor: 3.944

4.  Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.

Authors:  Daniel W Gunda; Christa Kasang; Benson R Kidenya; Rodrick Kabangila; Stephen E Mshana; Jeremiah Kidola; Samuel E Kalluvya; Gilbert W Kongola; Hartwig Klinker
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

5.  Trace Level Quantification of the (-)2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3-butyn-2-ol Genotoxic Impurity in Efavirenz Drug Substance and Drug Product Using LC-MS/MS.

Authors:  Nagadeep Jaishetty; Kamaraj Palanisamy; Arthanareeswari Maruthapillai; Rajamanohar Jaishetty
Journal:  Sci Pharm       Date:  2015-10-18

6.  Development and validation of reversed-phase HPLC gradient method for the estimation of efavirenz in plasma.

Authors:  Shweta Gupta; Rajesh Kesarla; Narendra Chotai; Abdelwahab Omri
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

7.  A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.

Authors:  Praveen Srivastava; Ganesh S Moorthy; Robert Gross; Jeffrey S Barrett
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.